Dahm F, Weber M
Division of Visceral and Transplantation Surgery, University Hospital Zürich, Switzerland.
Swiss Surg. 2003;9(5):205-12. doi: 10.1024/1023-9332.9.5.205.
The standard of care for patients with end-stage renal disease is kidney transplantation, which not only confers a survival benefit compared to hemodialysis, but is also cost-effective. The indications, contraindications as well as the preoperative assessment of recipients are discussed. The recurrence rate of the underlying renal disease has to be taken into account, especially in living donation. Growing organ shortage has lead transplant surgeons to accept older, less healthy, and even non-heart-beating donors, with generally good results. Living-donation is safe for the donor, outcome is excellent and plays an increasing role today. It has surpassed the number of cadaveric kidney transplantations in some countries. Many centres now apply laparoscopic donor nephrectomy with low morbidity. Matching for ABO blood group and HLA is routinely performed, as well as pre-transplant crossmatching. The surgical procedure has been standardized and the complication rate is low. Immunosuppressive protocols have evolved over time, and while the optimal regimen has not been defined, the availability of numerous agents allows the regimen to be individualized. New agents are being introduced into clinical practice. With increasing long-term graft survival and thus life-long immunosuppression, cardiovascular disease, de-novo malignancies and infectious complications are major causes of morbidity and mortality of transplant recipients. Effective prophylactic measures are often available, and surveillance protocols are warranted in these patients. Overall, the outcome of renal transplantation is excellent and has improved over time. Future prospects include induction of allograft tolerance, tissue engineering and xenotransplantation.
终末期肾病患者的标准治疗方法是肾移植,与血液透析相比,肾移植不仅能带来生存益处,而且具有成本效益。文中讨论了肾移植受者的适应证、禁忌证以及术前评估。必须考虑基础肾病的复发率,尤其是在活体供肾的情况下。日益严重的器官短缺促使移植外科医生接受年龄更大、健康状况较差甚至心跳已停的供者,总体效果良好。活体供肾对供者安全,效果极佳,如今发挥着越来越重要的作用。在一些国家,其数量已超过尸体肾移植。现在许多中心采用腹腔镜供肾切除术,并发症发生率较低。常规进行ABO血型和人类白细胞抗原(HLA)配型以及移植前交叉配型。手术操作已标准化,并发症发生率低。免疫抑制方案随着时间不断演变,虽然尚未确定最佳方案,但多种药物的出现使方案能够个体化。新药物正在引入临床实践。随着移植物长期存活率的提高以及因此需要终身免疫抑制,心血管疾病、新发恶性肿瘤和感染性并发症成为移植受者发病和死亡的主要原因。通常有有效的预防措施,对这些患者进行监测方案是必要的。总体而言,肾移植的效果极佳,且随着时间不断改善。未来前景包括诱导同种异体移植物耐受、组织工程和异种移植。